NIH Director's New Innovator Award

NIH Director's New Innovator Award

Supports early-stage researchers with transformative ideas in high-risk biomedical studies.

The NIH Director's New Innovator Award is part of the NIH Common Fund's High-Risk, High-Reward (HRHR) Research Program. Established in 2007, the award is specifically reserved for Early Stage Investigators — researchers who have completed their terminal degree or postdoctoral clinical training within the past ten years — and supports bold, innovative biomedical or behavioral research proposals that carry meaningful scientific risk but high potential impact. No preliminary data is required to apply, and the program explicitly encourages ideas that are too unconventional for traditional study sections.

Each award provides $475,000 per year for five years ($2.375 million total), and the FY2026 Congressional Budget Request allocates $69.402 million to the New Innovator program — the largest of the four HRHR awards by budget. Applications must be single-PI; multi-PI applications are not permitted. The investigator must commit at least 25% of their research effort to the award. Eligible hosts are U.S. universities and qualifying research organizations; for-profit entities cannot serve as the awardee institution.

Like all HRHR awards, funding opportunity announcements are released annually in the spring with fall application deadlines. The ten-year career-stage window is the defining eligibility gate — investigators who recently completed a PhD or clinical fellowship are the core audience. The New Innovator Award is designed to accelerate the careers of researchers who have a bold scientific idea but have not yet accumulated the publication record typically needed to compete for R01 funding, making it one of the most important federal mechanisms for emerging independent investigators.